CAMP4 Therapeutics
Highly Engaged Employees
Business Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1 Kendall Sq Fl 3 Bldg 1400, Cambridge, ...Phone Number
(617) 763-3412Website
www.camp4tx.comRevenue
<$5 MillionStock Symbol
CAMPIndustry
About CAMP4 Therapeutics
CAMP4 Therapeutics Org Chart
Is CAMP4 Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on CAMP4 Therapeutics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at CAMP4 Therapeutics
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once CAMP4 Therapeutics has new funding data
Click to see if CAMP4 Therapeutics had a recent Job posting/layoffs
Product Launch: Get notified when CAMP4 Therapeutics launches new products
Check out if CAMP4 Therapeutics is spiking on competitors!
Check if CAMP4 Therapeutics has recently received funding, and reach out quickly before it becomes old news!
CAMP4 Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at CAMP4 Therapeutics
Find more new buyers
Compare Similar Companies to CAMP4 Therapeutics
Compare insights from companies similar to CAMP4 Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
CAMP4 Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
CAMP4 Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about CAMP4 Therapeutics.
CAMP4 Therapeutics financials insights
Gather financial insights about CAMP4 Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
Series A
$30M
Other Financing Round
$45M
Series B
$100M
CAMP4 Therapeutics Tech Stack
A closer look at the technologies used by CAMP4 Therapeutics
Most Recent Scoops
CAMP4 Therapeutics News & Media
Is CAMP4 THERAPEUTICS CORPORATION (CAMP) Stock Undervalued Ahead of Key CMP-002 Clinical Development Milestones?
We recently compiled a list of the 8 Best Up and Coming Pharmaceutical Stocks to Buy Now. CAMP4 THERAPEUTICS CORPORATION (NASDAQ:CAMP) is one of the best up and coming stocks on our list. TheFly reported on June 16 that JPMorgan upgraded CAMP4 to Overweight from Neutral and increased its price target to $9 from $5. The […]CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., June 19, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on June 15, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted non-quCAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on May 15, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted a non-quCAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder
CMP-002 administration resulted in a statistically significant improvement in seizure phenotypes and parameters in a SYNGAP1 haploinsufficient mouse model
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding CAMP4 Therapeutics
At CAMP4 Therapeutics, we are revolutionizing drug discovery and development to be faster, smarter and better. With our Gene Circuitry Platform, we have discovered how to dial up or dial down the expression of any gene. Using the foundational insights enabled by our platform, we are pioneering a systematic and scalable approach to discover new, dru... Read More

